Faron Pharmaceuticals' board is excited about the company's prospects for 2017 and beyond.
Chief executive Dr Markku Jalkanen said: "We are getting close to read-out of the INTEREST trial, which we believe could revolutionise intensive care practices for ARDS patients.
"We are therefore continuing to prepare the business in anticipation of commercial launch soon after the trial results are received.
"In addition, the company continues to progress and expand its clinical development programme in order to increase indications targeted and maximise shareholder value.
"The company has made new hires and I would also like to take the opportunity to thank Dr Ilse Piippo for working with us since 2007 and building the current regulatory pathway for Traumakine.
"The skills and commitment she has shown over the years are still evident as she builds the road for treatment with Traumakine in paediatric applications.
"As a replacement, Dr Matti Karvonen has already demonstrated his strengths in the past eight months and I am confident that the Faron pipeline will progress well under his supervision."
At 9:06am: (LON:FARN) Faron Pharmaceuticals share price was +2.5p at 350p